Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protocol on a multicentre statistical and economic modelling study of risk-based stratified and personalised screening for diabetes and its complications in India (SMART India).
Sivaprasad S, Raman R, Rajalakshmi R, Mohan V, Deepa M, Das T, Ramasamy K, Prevost AT, Wittenberg R, Netuveli G, Lingam G, Hanif W, Ramakrishnan R, Ramu J, Surya J, Conroy D; SMART India Study Collaborators. Sivaprasad S, et al. Among authors: ramu j. BMJ Open. 2020 Dec 12;10(12):e039657. doi: 10.1136/bmjopen-2020-039657. BMJ Open. 2020. PMID: 33310798 Free PMC article.
Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial.
Sivaprasad S, Prevost AT, Bainbridge J, Edwards RT, Hopkins D, Kelly J, Luthert P, Murphy C, Ramu J, Sarafraz-Shekary N, Vasconcelos J, White-Alao B, Hykin P. Sivaprasad S, et al. Among authors: ramu j. BMJ Open. 2015 Sep 14;5(9):e008405. doi: 10.1136/bmjopen-2015-008405. BMJ Open. 2015. PMID: 26369798 Free PMC article. Clinical Trial.
Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT.
Sivaprasad S, Hykin P, Prevost AT, Vasconcelos J, Riddell A, Ramu J, Murphy C, Kelly J, Edwards RT, Yeo ST, Bainbridge J, Hopkins D, White-Alao B. Sivaprasad S, et al. Among authors: ramu j. Southampton (UK): NIHR Journals Library; 2018 Oct. Southampton (UK): NIHR Journals Library; 2018 Oct. PMID: 30303670 Free Books & Documents. Review.
Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy: A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial.
Gurudas S, Patrao N, Nicholson L, Sen P, Ramu J, Sivaprasad S, Hykin P. Gurudas S, et al. Among authors: ramu j. JAMA Ophthalmol. 2022 Feb 1;140(2):143-150. doi: 10.1001/jamaophthalmol.2021.5619. JAMA Ophthalmol. 2022. PMID: 34989804 Free PMC article. Clinical Trial.
Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
Hykin P, Prevost AT, Sivaprasad S, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Alshreef A, Flight L, Pennington R, Hounsome B, Lever E, Metry A, Poku E, Yang Y, Harding SP, Lotery A, Chakravarthy U, Brazier J. Hykin P, et al. Among authors: ramu j. Health Technol Assess. 2021 Jun;25(38):1-196. doi: 10.3310/hta25380. Health Technol Assess. 2021. PMID: 34132192 Free PMC article. Clinical Trial.
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial.
Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A, Chakravarthy U, Sivaprasad S; LEAVO Study Group. Hykin P, et al. Among authors: ramu j. JAMA Ophthalmol. 2019 Nov 1;137(11):1256-1264. doi: 10.1001/jamaophthalmol.2019.3305. JAMA Ophthalmol. 2019. PMID: 31465100 Free PMC article.
52 results